Premium
Lithium and valproate decrease the membrane phosphatidylinositol/phosphatidylcholine ratio
Author(s) -
Ding Daobin,
Greenberg Miriam L.
Publication year - 2003
Publication title -
molecular microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 247
eISSN - 1365-2958
pISSN - 0950-382X
DOI - 10.1046/j.1365-2958.2003.03284.x
Subject(s) - phosphatidylinositol , phosphatidylcholine , phospholipid , inositol , biology , intracellular , biochemistry , lithium (medication) , membrane , microbiology and biotechnology , signal transduction , endocrinology , receptor
Summary Lithium and valproate, two structurally different anti‐bipolar drugs, cause decreased intracellular inositol in the yeast Saccharomyces cerevisiae and an in‐crease in expression of a structural ( INO1 ) and a regulatory ( INO2 ) gene for phospholipid synthesis that responds to inositol depletion (Vaden, D., Ding, D., Peterson, B., and Greenberg, M.L., 2001, J Biol Chem 276: 15466–15471). We report here that both drugs decrease the relative rate of membrane phosphatidylinositol synthesis and, to a lesser but still significant degree, the steady state relative phosphatidylinositol composition. In addition, both drugs increase the rate of phosphatidylcholine (PC) synthesis. Finally, valproate, but not lithium, increases expression of phosphatidylcholine pathway genes CHO1 and OPI3 . The overall effect on membrane phospholipid composition is a reduction in the phosphatidylinositol/phosphatidylcholine ratio by both drugs. Because maintenance of the appropriate phosphatidylinositol/phosphatidylcholine ratio is required for secretory vesicle formation, a decrease in this ratio may have far‐reaching implications for understanding the therapeutic mechanisms of action of these drugs.